News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pegasus Pharmaceuticals Inc. Acquires Worldwide Marketing Rights To Effective Biological-Concept Mold Remove System -- Laboratory Tests Successfully Completed


1/8/2007 11:03:04 AM

PALM BEACH GARDENS, FL -- (MARKET WIRE) -- January 08, 2007 -- Pegasus Pharmaceuticals (PINKSHEETS: PGUZ) today announced that it has acquired the worldwide marketing rights to an innovative new biological product called the Mold Remove System, which has recently completed a series of rigorous independent laboratory tests during 2006.

The control and elimination of mold has become a multi-billion-dollar market worldwide. Molds consist of such fungi as Aspergillus sp., Cladosporium sp., Fusarium sp., Penicillum sp. and others. One of the most frequently cited fungi is Stachybotrys Chartarum, commonly known as black mold. Often referred to as mildew, molds are a subset of fungi that produce fluffy or powdery growth on surfaces such as cloth, carpets, leather, wood, sheetrock, insulation and even food. They may grow at high levels indoors in homes or buildings under ideal conditions which include moisture, proper nutrients, temperature and certain levels of light. Toxic black mold can cause severe health problems including allergic reactions, headaches, skin disease, fungal infections, sinus problems, asthma and a litany of other human diseases that are now being connected to molds.

Highlighted Links Pegasus/HeartView, LLC

Pegasus' new product, the Mold Remove System (MRS), is based on a new biological concept which controls the mold spores and prevents their growth. It is a multi-component mold control system which removes black mold infestation, cleans and disinfects surfaces and has long-lasting effects on the prevention of future mold growth. MRS consists of a unique combination of non-toxic, biodegradable ingredients. Other mold prevention products on the market involve chemically aggressive, hazardous and harmful compounds which are only temporarily effective. Pegasus' Mold Remove System is a new generation biological system which is not harmful to humans. It may be utilized safely in any home, school, hospital or commercial environment without any specific precautions.

The Company's MRS product performed extremely well in a series of rigorous independent laboratory tests, the most recent being performed by ECA Inc., a preeminent testing laboratory based in San Diego, California. ECA tested the product on two pieces of drywall material. Both were treated with black mold consisting of Stachybotrys Chartarum, Aspergillus sp. and Penicillum sp. Both surfaces were kept in high humidity conditions of 80-90% at +4 degrees Centigrade. After initial growth of black mold, one of the surfaces was treated with MRS. Both treated and untreated surfaces were observed for a period of sixty days. The untreated surface exhibited typical mold growth, which spread to approximately 80% of the surface. The Mold Remove System was effective in black mold cleaning, as well as its growth. After sixty days of the experiment, no mold growth was observed on the treated drywall surface. The product demonstrated 100% efficiency against growth of the black mold fungi. MRS has effectively shown that not only does it clean and disinfect surfaces, but that it kills all fungi cells and black mold spores while preventing future spore growth.

Pegasus is now implementing an integrated marketing campaign in North America and Europe for the introduction of its Mold Remove System featuring its safe, easy-to-use application, its ability to prevent future mold growth and the fact that it is environmentally friendly.

For more information, please contact Paul Davey, Investor Services at (778) 389-0915 (Canada). Email: paul@pegasusbiosciences.com, or Daniel P. Kesonen, Chairman and CEO of Pegasus Pharmaceuticals Inc., Palm Beach, Florida at (561) 626-9901. Details of the Company's new mold product will be posted on the corporate website: www.pegasusbiosciences.com as soon as details become available.

Contact: Paul Davey Investor Services (778) 389-0915 (Canada) Email: paul@pegasusbiosciences.com

Daniel P. Kesonen Chairman and CEO Pegasus Pharmaceuticals Inc. Palm Beach, Florida (561) 626-9901

SOURCE: Pegasus Pharmaceuticals Inc.

>>> Discuss This Story


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES